Key facts
- This page summarizes Chad Gassert's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Nov 2021, 15:44.
Chad Gassert - 19 Nov 2021 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)
- Reporting relationship
- SVP - CORP. DEV. & STRATEGY
- Issuer ticker
- ANIP
- Reported as of
- 19 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Nov 2021, 15:44:43 UTC
- Next SEC filing
- 22 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chad Gassert
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chad Gassert filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 23 Nov 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANIP
transaction
Common Stock
Award
- Transaction value
- Shares
- +383,226
- Change %
- Price
- Shares after
- 383,226
- Date
- 19 Nov 2021
- Ownership
- Held by Chali Properties LLC
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 2,000,000 Company Interests of Novitium held by Chali Properties LLC were converted into 383,226 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
Footnote F2
The Reporting Person holds voting and dispositive power over the shares held by Chali Properties LLC.